Adapting to the long pandemic

Multivariable analysis showed significant differences in progression free and overall survival for the proton pump use but not antibiotic use. Over a 5-year study period, the baseline AGEs did not correlate with PSQI score or nocturia; however, with follow-up, the PSQI score increased significantly in the AGEs' high group, but no change with nocturia. The drug of interest is enfortumab vedotin, an anti-Nectin-4 antibody–drug conjugate that is approved for progression after platinum-based chemotherapy. In this study, the mutations did not influence clinical outcomes such as objective responses rates, progression-free survival or overall survival.